Industry / United Kingdom
GlaxoSmithKline's Centre Of Excellence For External Drug Discovery Invests In Prosensa
October 2009 | Industry Trend AnalysisFollowing UK drugmaker GlaxoSmithKline (GSK)'s Centre of Excellence for External Drug Discovery (CEEDD)'s June 2009 alliance with Chroma Therapeutics, the company's drug discovery centre has signed a deal with Dutch-based biopharmaceutical company, Prosensa for the development and commercialisation of RNA-based therapeutics for Duchenne Muscular Dystrophy (DMD).
To read the full article, please choose one of the following options:
Subcribers please log in




